Quercetin inhibits angiogenesis–mediated human retinoblastoma growth by targeting vascular endothelial growth factor receptor

Oncology Letters

Volumn 14, Issue 3, 2017, Pages 3343-3348

  Song, Wei ^a   Zhao, Xiaofei ^a   Xu, Jiarui ^b   Zhang, Han ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Quercetin; Retinoblastoma; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; FLAVONOID; MESSENGER RNA; QUERCETIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNTING; CELL GROWTH ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROTEIN EXPRESSION; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

EID: 85026305290     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6623     Document Type: Article

References (35)

1. Menon BS, Alagaratnam J, Juraid EA, Mohamed M, Ibrahim H and Naing NN: Late presentation of retinoblastoma in Malaysia. Pediatr Blood Cancer 52: 215–217, 2009.
2. Bowman RJ, Mafwir MI, Luther P, Luande J and Wood M: Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer 50: 160–162, 2008.
3. Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ and Boyd NW: Presenting signs of retinoblastoma. J Pediatr 132: 505–508, 1998.
4. Kivelä T: The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Brit J Ophthalmol 93: 1129–1131, 2009.
5. Leal–Leal C, Flores–Rojo M, Medina–Sansón A, Cerecedo–Díaz F, Sánchez–Félix S, González–Ramella O, Pérez–Pérez F, Gómez–Martínez R, Quero–Hernández A, Altamirano–Alvarez E, et al: A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol 88: 1074–1077, 2004.
6. Comings DE: A general theory of carcinogenesis. Proc Natl Acad Sci USA 70: 3324–3328, 1973.
7. Friend SH, Bernards RA, Rogelj S, Weinberg RA, Rapaport JM, Albert DM and Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643–646, 1986.
8. Alfred G and Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820–823, 1971.
9. Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS and Gallie BL: Retinoblastoma. Lancet 379: 1436–1446, 2012.
10. Shields CL and Shields JA: Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 17: 228–234, 2006.
11. Saxena P and Kaur J: Differential expression of genes in retinoblastoma. Clin Chim Acta 412: 2015–2021, 2011.
12. Rossler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schüler A, Bornfeld N and Schilling H: Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol 164: 391–394, 2004.
13. Marback EF, Arias VEA, Paranhos A Jr, Soares FA, Murphree AL and Erwenne CM: Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol 87: 1224–1228, 2003.
14. Houston SK, Murray TG, Wolfe SQ and Fernandes CE: Current update on retinoblastoma. Int Ophthalmol Clin 51: 77–91, 2011.
15. Slusarz A, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, MacDonald RS, Besch–Williford CL and Lubahn DB: Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res 70: 3382–3390, 2010.
16. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Gálvez J and Zarzuelo A: In vivo quercitrin anti–inflammatory effect involves release of quercetin, which inhibits inflammation through down–regulation of the NF–kappaB pathway. Eur J Immunol 35: 584–592, 2005.
17. Murakami A, Ashida H and Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett 269: 315–325, 2008.
18. Granado–Serrano AB, Martin MA, Bravo L, Goya L and Ramos S: Quercetin induces apoptosis via caspase activation, regulation of Bcl–2 and inhibition of PI–3–kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 136: 2715–2721, 2006.
19. Duraj J, Zazrivcova K, Bodo J, Sulikova M and Sedlak J: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 52: 273–279, 2004.
20. Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR–2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real–time quantitative PCR and the 2(–Dela Delta C(T)) method. Methods 25: 402–408, 2001.
22. Merriam GR Jr: Retinoblastoma; analysis of 17 autopsies. Arch Ophthal 44: 71–108, 1950.
23. Carbajal UM: Metastasis in retinoblastoma. Am J Ophthalmol 48: 47–69, 1959.
24. Taktikos A: Investigation of retinoblastoma with special reference to histology and prognosis. Br J Ophthalmol 50: 225–234, 1966.
25. Rubin CM, Robison LL, Cameron JD, Woods WG, Nesbit ME Jr, Krivit W, Kim TH, Letson RD and Ramsay NK: Intraocular retinoblastoma group V: An analysis of prognostic factors. J Clin Oncol 3: 680–685, 1985.
26. Kopelman JE, McLean IW and Rosenberg SH: Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology 94: 371–377, 1987.
27. Liu Q, Wang Y, Wang H, Liu Y, Liu T and Kunda PE: Tandem therapy for retinoblastoma: Immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol 139: 1357–1372, 2013.
28. Ren MX, Deng XH, Ai F, Yuan GY and Song HY: Effect of quercetin on the proliferation of the human ovarian cancer cell line SKOV–3 in vitro. Exp Ther Med 10: 579–583, 2015.
29. Park CH, Chang JY, Hahm ER, Park S, Kim HK and Yang CH: Quercetin, a potent inhibitor against beta–catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 328: 227–234, 2005.
30. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58–61, 1989.
31. Liotta LA, Steeg PS and Stetler–Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327–336, 1991.
32. Tang N, Shi L, Yu Z, Dong P, Wang C, Huo X, Zhang B, Huang S, Deng S, Liu K, et al: Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF–induced angiogenesis by suppressing VEGFR–2 signaling pathway. Oncotarget 7: 3533–3547, 2016.
33. Zhang Z, Zhang H, Peng T, Li D and Xu J: Melittin suppresses cathepsin S–induced invasion and angiogenesis via blocking of the VEGF–A/VEGFR–2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma. Oncol Lett 11: 610–618, 2016.
34. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J and Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309–1312, 1989.
35. Tie J and Desai J: Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog 17: 51–67, 2012.